[ad_1]
The announcement that the potential coronavirus vaccine developed by the French pharmaceutical group Sanofi would prioritize the United States provoked strong reactions from the Gallic Government and the European Union.
(It may interest you: Confirm presence of the new coronavirus in dogs)
The President of France, Emmanuel Macron, estimated that the covid-19 vaccine must be “a global public good”. “The efforts made in recent months show the need for this vaccine to be a global public good, outside the laws of the market,” said the French presidency.
The Elysee Palace added that Macron will receive the leaders of Sanofi early next week. It is important to maintain “the multiple efforts (…) to build around multinational actors a collective and coordinated response” to the pandemic, added the French presidency.
(We suggest: Covid-19: younger ones catch, but more older adults die)
The pharmaceutical group created controversy on Wednesday after claiming that would give priority to the United States in case of finding a vaccine, because the American authorities have made important investments and have partnered with the company in the search for the vaccine.
The US government would be “entitled to the largest orders,” since this country “has invested” and “shares the risk,” said the group’s CEO, Paul Hudson, in an interview with the Bloomberg agency.
Meanwhile, the vice president of the European Commission for the Promotion of the European Lifestyle, Margaritis Schinas, said Thursday that once a coronavirus vaccine is developed – whatever it may be -:
(Also read: The treatments and vaccines they are investigating to fight the coronavirus)
Producing the vaccine is only half the battle ahead of us. We also have to ensure fair, comprehensive and equal access to the vaccine as soon as possible.
“Producing the vaccine is only half the battle that lies ahead. We also have to ensure fair, comprehensive and equal access to the vaccine as soon as possible; not only for all Europeans, but also for the rest of the world, ”Schinas said in an appearance before the European Parliament.
The Greek commissioner noted that this can be achieved through public-private partnerships, an increase in manufacturing capacity or by providing guarantees to the production of immunizations.
Schinas explained that the Community Executive is already in contact with the European national governments and the producers of vaccines to identify in advance how the Member States can be supported in the purchase and distribution of the vaccines, once they have been developed and tested.
“We do not exclude any options,” said the commissioner, who also said that Brussels is in contact with the European Medicines Agency to speed up the process of approving vaccine candidates as safely as possible.
Schinas explained that, Of the eight candidates in clinical evaluation and 94 in preclinical identified by the World Health Organization, the European Union is financially supporting the development of three of them through the Horizon 2020 community research program.
Earlier this month, the European Commission led an international donor conference to develop new diagnostic methods, treatments and a universal coronavirus vaccine, which raised € 7.4 billion against the pandemic.
The figure reached was close to the expected target of 7,500 million euros (8,000 million dollars), of which around 53% will go to future vaccines; 26% to research new medicines, and 20% to develop tests.
Sanofi’s response
Sanofi “needs to share the risks” to make a vaccine against covid-19 before its formal authorization, which the United States did according to a “model” that “does not exist in Europe,” the director general of the French laboratory insisted on Thursday, Paul Hudson.
“It’s a risk we must share,” said Hudson. in an interview with the Financial Times. “There is a lot of will in Europe (…), the next stage will be (manufacturing) the instrument to guarantee that we are capable of ensuring production in Europe and in the rest of the world,” he added.
Sanofi, one of the world’s most powerful vaccine specialists, launched in search of a vaccine in February and signed a cooperation agreement with the Advanced Biomedical Research and Development Authority (Barda), which reports to the US Ministry of Health. .
Regarding the investigation itself, it was confirmed that The goal was still to develop a usable vaccine within 18-24 months. This term is extremely fast compared to the normal term of about 10 years, the pharmacist said.
HEALTH UNIT
See here all the news from the EL TIEMPO Health Unit.
Contact us through @SaludET, on Twitter, or in the email [email protected].
[ad_2]
